Jazz Pharmaceuticals shared a post on LinkedIn:
“News for U.S. media and investors: On Thursday at ASCO GI26, we will present positive Phase 3 trial results from our HER2-targeted therapy in first-line HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
These results underscore our ongoing commitment to advancing the current standards of care available for HER2-targeted cancers, like metastatic GEA.
More from ASCO GI26.